Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHAPSODY: 3K3A-APC in Acute Ischemic Stroke
NCT02222714Phase 2Completed
- Sponsor
- ZZ Biotech
- Start
- Oct 2014
- Primary completion
- Apr 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 3K3A-APC in ischemic stroke (5 arms), sponsored by ZZ Biotech. Primary endpoint: Dose-limiting Toxicity at 48 hours. Started Oct 2014; status: completed.
02
Drugs
3K3A-APC
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02222714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222714.